ClinicalTrials.gov
Cure8 trial brief
Why This Matters
The trial explores whether morning bright light therapy can improve gut barrier function, inflammation, the microbiome, and quality of life in people with IBD who have disrupted sleep/circadian patterns—potentially offering a non-drug way to reduce factors linked to flares and poorer outcomes.
Who Should Pay Attention
Adults with Crohn's disease or ulcerative colitis (especially those with fatigue or sleep/circadian disruption), clinicians managing IBD, and researchers studying microbiome, intestinal permeability, or sleep-related interventions.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment30 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This is a randomized crossover interventional trial recruiting at Rush University Medical Center and Medical University of South Carolina.
Eligible adults with biopsy-proven Crohn's or ulcerative colitis who show both subjective and actigraphy-confirmed morning circadian/morning dysfunction (CM) and meet fecal calprotectin or CRP/fatigue thresholds will be randomized to 4 weeks of bright light therapy via Re-Timer glasses or a placebo (non-light) device, then cross over.
The study collects urine sugar tests for intestinal permeability, blood for inflammatory/endotoxemia markers, and stool for shotgun metagenomic sequencing before and after each treatment period. The Re-Timer device is described as a general wellness product and is not FDA-regulated as a medical device.
Keep In Mind
Small crossover mechanistic trial (planned N=30). The device used is marketed as a general wellness product and not regulated by the FDA. The study focuses on biomarker and microbiome changes; it does not yet provide evidence that light therapy prevents flares or should replace standard IBD treatments.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorRush University Medical Center
Trial IDNCT05579392
Study typeInterventional
Trial phaseNA
Enrollment30 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedOct 28, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Understanding role of microbiota in Crohn's disease, ulcerative colitis
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
Wild Blueberries in Colitis
This trial examines whether a blueberry-rich supplement can change inflammation, the microbiome, and intestinal barrier function in people with chronic colitis — topics many with IBD care about because diet and the...
A very common vitamin has surprised scientists and is forcing them to rethink how to manage inflammation in Crohn’s disease and colitis
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.